Search Results - "Sandro Pignata"

Management of Platinum-Resistant, Relapsed Epithelial Ovarian Cancer and New Drug Perspectives by Pujade-Lauraine, Eric, Banerjee, Susana, Pignata, Sandro

Get full text

Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer by Ray-Coquard, Isabelle, Pautier, Patricia, Pignata, Sandro, Pérol, David, González-Martín, Antonio, Berger, Regina, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mäenpää, Johanna, Selle, Frédéric, Sehouli, Jalid, Lorusso, Domenica, Guerra Alía, Eva M, Reinthaller, Alexander, Nagao, Shoji, Lefeuvre-Plesse, Claudia, Canzler, Ulrich, Scambia, Giovanni, Lortholary, Alain, Marmé, Frederik, Combe, Pierre, de Gregorio, Nikolaus, Rodrigues, Manuel, Buderath, Paul, Dubot, Coraline, Burges, Alexander, You, Benoît, Pujade-Lauraine, Eric, Harter, Philipp

“…When used as maintenance therapy, the PARP inhibitor olaparib provided a significant progression-free survival benefit in women with ovarian cancer who had a…”
Get full text

Treatment of recurrent epithelial ovarian cancer by Pignata, Sandro, Pisano, Carmela, Di Napoli, Marilena, Cecere, Sabrina Chiara, Tambaro, Rosa, Attademo, Laura

“…The majority of patients with advanced ovarian cancer progress after first‐line therapy and require further treatment. Tumor biology, prior chemotherapy,…”
Get full text

Atezolizumab, Bevacizumab, and Chemotherapy for Newly Diagnosed Stage III or IV Ovarian Cancer: Placebo-Controlled Randomized Phase III Trial (IMagyn050/GOG 3015/ENGOT-OV39) by Moore, Kathleen N, Bookman, Michael, Sehouli, Jalid, Miller, Austin, Anderson, Charles, Scambia, Giovanni, Myers, Tashanna, Taskiran, Cagatay, Robison, Katina, Mäenpää, Johanna, Willmott, Lyndsay, Colombo, Nicoletta, Thomes-Pepin, Jessica, Liontos, Michalis, Gold, Michael A, Garcia, Yolanda, Sharma, Sudarshan K, Darus, Christopher J, Aghajanian, Carol, Okamoto, Aikou, Wu, Xiaohua, Safin, Rustem, Wu, Fan, Molinero, Luciana, Maiya, Vidya, Khor, Victor K, Lin, Yvonne G, Pignata, Sandro

“…To evaluate the addition of the humanized monoclonal antiprogrammed death ligand-1 (PD-L1) antibody, atezolizumab, to platinum-based chemotherapy and…”
Get full text

Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study by Coleman, Robert L, Lorusso, Domenica, Gennigens, Christine, González-Martín, Antonio, Randall, Leslie, Cibula, David, Lund, Bente, Woelber, Linn, Pignata, Sandro, Forget, Frederic, Redondo, Andrés, Vindeløv, Signe Diness, Chen, Menghui, Harris, Jeffrey R, Smith, Margaret, Nicacio, Leonardo Viana, Teng, Melinda S L, Laenen, Annouschka, Rangwala, Reshma, Manso, Luis, Mirza, Mansoor, Monk, Bradley J, Vergote, Ignace, Raspagliesi, Francesco, Melichar, Bohuslav, Gaba Garcia, Lydia, Jackson, Amanda, Henry, Stephanie, Kral, Zdenek, Harter, Philipp, De Giorgi, Ugo, Bjurberg, Maria, Gold, Michael, O'Malley, David, Honhon, Brigitte, Vulsteke, Christof, De Cuypere, Eveline, Denys, Hannelore, Baurain, Jean-Francois, Zamagni, Claudio, Tenney, Meaghan, Gordinier, Mary, Bradley, William, Schlumbrecht, Matthew, Spirtos, Nicola, Concin, Nicole, Mahner, Sven, Scambia, Giovanni, Leath, Charles, Farias-Eisner, Robin, Cohen, Joshua, Muller, Carolyn, Bhatia, Sumeet

“…Few effective second-line treatments exist for women with recurrent or metastatic cervical cancer. Accordingly, we aimed to evaluate the efficacy and safety of…”
Get full text

Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study by Bagnoli, Marina, PhD, Canevari, Silvana, PhD, Califano, Daniela, PhD, Losito, Simona, MD, Maio, Massimo Di, Prof, Raspagliesi, Francesco, MD, Carcangiu, Maria Luisa, MD, Toffoli, Giuseppe, MD, Cecchin, Erika, PhD, Sorio, Roberto, MD, Canzonieri, Vincenzo, MD, Russo, Daniela, PhD, Scognamiglio, Giosué, PhD, Chiappetta, Gennaro, PhD, Baldassarre, Gustavo, MD, Lorusso, Domenica, MD, Scambia, Giovanni, Prof, Zannoni, Gian Franco, Prof, Savarese, Antonella, MD, Carosi, Mariantonia, MD, Scollo, Paolo, MD, Breda, Enrico, MD, Murgia, Viviana, MD, Perrone, Francesco, MD, Pignata, Sandro, MD, De Cecco, Loris, PhD, Mezzanzanica, Delia, Dr

“…Summary Background Risk of relapse or progression remains high in the treatment of most patients with epithelial ovarian cancer, and development of a molecular…”
Get full text

Incorporation of pazopanib in maintenance therapy of ovarian cancer by du Bois, Andreas, Floquet, Anne, Kim, Jae-Weon, Rau, Joern, del Campo, Josep M, Friedlander, Michael, Pignata, Sandro, Fujiwara, Keiichi, Vergote, Ignace, Colombo, Nicoletta, Mirza, Mansoor R, Monk, Bradley J, Kimmig, Rainer, Ray-Coquard, Isabelle, Zang, Rongyu, Diaz-Padilla, Ivan, Baumann, Klaus H, Mouret-Reynier, Marie-Ange, Kim, Jae-Hoon, Kurzeder, Christian, Lesoin, Anne, Vasey, Paul, Marth, Christian, Canzler, Ulrich, Scambia, Giovanni, Shimada, Muneaki, Calvert, Paula, Pujade-Lauraine, Eric, Kim, Byoung-Gie, Herzog, Thomas J, Mitrica, Ionel, Schade-Brittinger, Carmen, Wang, Qiong, Crescenzo, Rocco, Harter, Philipp

“…Pazopanib is an oral, multikinase inhibitor of vascular endothelial growth factor receptor (VEGFR) -1/-2/-3, platelet-derived growth factor receptor (PDGFR)…”
Get full text

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial by du Bois, Andreas, Prof, Kristensen, Gunnar, Prof, Ray-Coquard, Isabelle, Prof, Reuss, Alexander, MSc, Pignata, Sandro, MD, Colombo, Nicoletta, Prof, Denison, Ursula, MD, Vergote, Ignace, Prof, del Campo, Jose M, MD, Ottevanger, Petronella, PhD, Heubner, Martin, MD, Minarik, Thomas, PhD, Sevin, Emmanuel, MD, de Gregorio, Nikolaus, MD, Bidziński, Mariusz, Prof, Pfisterer, Jacobus, Prof, Malander, Susanne, MD, Hilpert, Felix, Prof, Mirza, Mansoor R, MD, Scambia, Giovanni, Prof, Meier, Werner, Prof, Nicoletto, Maria O, MD, Bjørge, Line, Prof, Lortholary, Alain, MD, Sailer, Martin Oliver, PhD, Merger, Michael, MD, Harter, Philipp, MD

“…Summary Background Angiogenesis is a target in the treatment of ovarian cancer. Nintedanib, an oral triple angiokinase inhibitor of VEGF receptor,…”
Get full text

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications by Giannone, Gaia, Attademo, Laura, Scotto, Giulia, Genta, Sofia, Ghisoni, Eleonora, Tuninetti, Valentina, Aglietta, Massimo, Pignata, Sandro, Valabrega, Giorgio

“…Endometrial cancer (EC) is the most frequent gynecological cancer. In patients with relapsed and advanced disease, prognosis is still dismal and development of…”
Get full text

Microsatellite Instability: From the Implementation of the Detection to a Prognostic and Predictive Role in Cancers by Amato, Martina, Franco, Renato, Facchini, Gaetano, Addeo, Raffaele, Ciardiello, Fortunato, Berretta, Massimiliano, Vita, Giulia, Sgambato, Alessandro, Pignata, Sandro, Caraglia, Michele, Accardo, Marina, Zito Marino, Federica

“…Microsatellite instability (MSI) has been identified in several tumors arising from either germline or somatic aberration. The presence of MSI in cancer…”
Get full text

Randomized Phase II Trial of Ridaforolimus in Advanced Endometrial Carcinoma by Oza, Amit M, Pignata, Sandro, Poveda, Andres, McCormack, Mary, Clamp, Andrew, Schwartz, Benjamin, Cheng, Jonathan, Li, Xiaoyun, Campbell, Kristy, Dodion, Pierre, Haluska, Frank G

“…The prognosis for women with recurrent and metastatic endometrial cancer is poor, and improved therapies are needed. The mammalian target of rapamycin (mTOR)…”
Get full text

microRNA signature defines chemoresistance in ovarian cancer through modulation of angiogenesis by Vecchione, Andrea, Belletti, Barbara, Lovat, Francesca, Volinia, Stefano, Chiappetta, Gennaro, Giglio, Simona, Sonego, Maura, Cirombella, Roberto, Onesti, Elisa Concetta, Pellegrini, Patrizia, Califano, Daniela, Pignata, Sandro, Losito, Simona, Canzonieri, Vincenzo, Sorio, Roberto, Alder, Hansjuerg, Wernicke, Dorothee, Stoppacciaro, Antonella, Baldassarre, Gustavo, Croce, Carlo M.

“…Epithelial ovarian cancer is the most lethal gynecologic malignancy; it is highly aggressive and causes almost 125,000 deaths yearly. Despite advances in…”
Get full text

Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse by PUJADE-LAURAINE, Eric, WAGNER, Uwe, SEHOULI, Jalid, LORTHOLARY, Alain, KRISTENSEN, Gunnar, JACKISCH, Christian, JOLY, Florence, BROWN, Chris, LE FUR, Nathalie, DU BOIS, Andreas, AAVALL-LUNDQVIST, Elisabeth, GEBSKI, Val, HEYWOOD, Mark, VASEY, Paul A, VOLGGER, Birgit, VERGOTE, Ignace, PIGNATA, Sandro, FERRERO, Annamaria

“…This randomized, multicenter, phase III noninferiority trial was designed to test the efficacy and safety of the combination of pegylated liposomal doxorubicin…”
Get full text

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001 by Marth, Christian, Tarnawski, Rafal, Tyulyandina, Alexandra, Pignata, Sandro, Gilbert, Lucy, Kaen, Diego, Rubio, M Jesús, Frentzas, Sophia, Beiner, Mario, Magallanes-Maciel, Manuel, Farrelly, Laura, Choi, Chel Hun, Berger, Regina, Lee, Christine, Vulsteke, Christof, Hasegawa, Kosei, Braicu, Elena Ioanna, Wu, Xiaohua, McKenzie, Jodi, Lee, John J, Makker, Vicky

“…Pembrolizumab plus lenvatinib is a novel combination with promising efficacy in patients with advanced and recurrent endometrial cancer. This combination…”
Get more information

Identification of a distinct population of CD133+CXCR4+ cancer stem cells in ovarian cancer by Cioffi, Michele, D’Alterio, Crescenzo, Camerlingo, Rosalba, Tirino, Virginia, Consales, Claudia, Riccio, Anna, Ieranò, Caterina, Cecere, Sabrina Chiara, Losito, Nunzia Simona, Greggi, Stefano, Pignata, Sandro, Pirozzi, Giuseppe, Scala, Stefania

“…CD133 and CXCR4 were evaluated in the NCI-60 cell lines to identify cancer stem cell rich populations. Screening revealed that, ovarian OVCAR-3, -4 and -5 and…”
Get full text

Pazopanib plus weekly paclitaxel versus weekly paclitaxel alone for platinum-resistant or platinum-refractory advanced ovarian cancer (MITO 11): a randomised, open-label, phase 2 trial by Pignata, Sandro, Dr, Lorusso, Domenica, MD, Scambia, Giovanni, Prof, Sambataro, Daniela, MD, Tamberi, Stefano, MD, Cinieri, Saverio, MD, Mosconi, Anna M, MD, Orditura, Michele, MD, Brandes, Alba A, MD, Arcangeli, Valentina, MD, Panici, Pierluigi Beneditti, Prof, Pisano, Carmela, MD, Cecere, Sabrina C, MD, Di Napoli, Marilena, MD, Raspagliesi, Francesco, MD, Maltese, Giuseppa, MD, Salutari, Vanda, MD, Ricci, Caterina, MD, Daniele, Gennaro, MD, Piccirillo, Maria Carmela, MD, Di Maio, Massimo, MD, Gallo, Ciro, Prof, Perrone, Francesco, MD

“…Summary Background Inhibition of angiogenesis is a valuable treatment strategy for ovarian cancer. Pazopanib is an anti-angiogenic drug active in ovarian…”
Get full text

Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer by FERRANDINA, Gabriella, LUDOVISI, Manuela, SCAMBIA, Giovanni, LORUSSO, Domenica, PIGNATA, Sandro, BREDA, Enrico, SAVARESE, Antonella, DEL MEDICO, Pietro, SCALTRITI, Laura, KATSAROS, Dionyssios, PRIOLO, Domenico

“…We aimed at investigating the efficacy, tolerability, and quality of life (QOL) of gemcitabine (GEM) compared with pegylated liposomal doxorubicin (PLD) in the…”
Get full text

Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report by Passarelli, Anna, Pisano, Carmela, Coppola, Elisabetta, Ventriglia, Jole, Cecere, Sabrina Chiara, Di Napoli, Marilena, Carideo, Luciano, Lastoria, Secondo, Pignata, Sandro

“…Cervical cancer (CC) is the second most commonly diagnosed cancer and the third leading cause of cancer death among females. The options of treatment for…”
Get full text

International multicenter real-world REGistry for patients with metastatic renAL cell carcinoma - Meet-URO 33 study (REGAL study) by Rebuzzi, Sara Elena, Fornarini, Giuseppe, Signori, Alessio, Buti, Sebastiano, Procopio, Giuseppe, De Giorgi, Ugo, Pignata, Sandro, Naglieri, Emanuele, Maruzzo, Marco, Banna, Giuseppe Luigi, Rescigno, Pasquale, Messina, Carlo, Mattana, Alvise, Basso, Umberto, Bimbatti, Davide

“…Nowadays, different therapeutic options are available for the first-line treatment of metastatic renal cell carcinoma (mRCC). Immuno-combinations are the…”
Get full text

Endometrial carcinosarcoma by Bogani, Giorgio, Ray-Coquard, Isabelle, Concin, Nicole, Ngoi, Natalie Yan Li, Morice, Philippe, Caruso, Giuseppe, Enomoto, Takayuki, Takehara, Kazuhiro, Denys, Hannelore, Lorusso, Domenica, Coleman, Robert, Vaughan, Michelle M, Takano, Masashi, Provencher, Diane Michele, Sagae, Satoru, Wimberger, Pauline, Póka, Robert, Segev, Yakir, Kim, Se Ik, Kim, Jae-Weon, Candido Dos Reis, Francisco Jose, Ramirez, Pedro T, Mariani, Andrea, Leitao, Mario, Makker, Vicky, Abu-Rustum, Nadeem R, Vergote, Ignace, Zannoni, Gianfranco, Tan, David, McCormack, Mary, Paolini, Biagio, Bini, Marta, Raspagliesi, Francesco, Benedetti Panici, Pierluigi, Di Donato, Violante, Muzii, Ludovico, Colombo, Nicoletta, Pignata, Sandro, Scambia, Giovanni, Monk, Bradley J

“…Endometrial carcinosarcoma is a rare and aggressive high-grade endometrial carcinoma with secondary sarcomatous trans-differentiation (conversion theory). The…”
Get more information